Acamprosate ( DrugBank: Acamprosate )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	1
206	Fragile X syndrome	3

6. Parkinson disease

---

Clinical trials : 2,307 /  Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00640952 (ClinicalTrials.gov)	August 2006	28/12/2007	Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease	Acamprosate for Treatment of Compulsive Behaviors and Craving in Parkinson's Disease	Parkinson's Disease	Drug: acamprosate	Baylor College of Medicine	National Parkinson Foundation	Withdrawn	18 Years	N/A	Both	0	N/A	United States

206. Fragile X syndrome

---

Clinical trials : 108 /  Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02998151 (ClinicalTrials.gov)	January 2016	1/12/2016	Neurophysiological and Acute Pharmacological Studies in FXS Patients	Neurophysiological and Acute Pharmacological Studies in FXS Patients	Fragile X Syndrome	Drug: Acamprosate;Drug: Lovastatin;Drug: Minocycline;Drug: Placebo;Drug: Baclofen	Children's Hospital Medical Center, Cincinnati	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	15 Years	55 Years	All	29	Early Phase 1	United States
2	NCT01911455 (ClinicalTrials.gov)	August 27, 2013	26/7/2013	Study of Acamprosate in Fragile x Syndrome	Double-Blind, Placebo-Controlled Proof of Concept Study in Youth With Fragile X Syndrome	Fragile X Syndrome	Drug: acamprosate;Drug: Placebo	Children's Hospital Medical Center, Cincinnati	Rush University Medical Center	Completed	5 Years	23 Years	All	46	Phase 1	United States
3	NCT01300923 (ClinicalTrials.gov)	August 2010	25/8/2010	Acamprosate in Youth With Fragile X Syndrome	Pilot Study of Acamprosate in Youth With Fragile X Syndrome	Fragile X Syndrome;Autism Spectrum Disorders	Drug: Acamprosate	Indiana University	NULL	Completed	5 Years	17 Years	All	14	Phase 2	United States